The global high content screening market size was valued at USD 909 Million in 2022 and is projected to reach USD 2.19 Billion by 2031, expanding at a CAGR of 10.3% during the forecast period, 2023 – 2031. The growth of the market is attributed to increasing use of this technique for testing the potential toxicity of chemicals and complex substances by pharmaceutical companies to improve in-vitro toxicity testing, which the time and cost for them.
High content screening (HCS) is an image-based screening technique, which measures the physical and biochemical characteristics in the cells and the organisms. It includes a software for image capturing, evaluation, and data storage. New product launches are resulting in product assortment, which has increased installation of HCS instruments. Instruments with enhanced cell imaging and analysis are preferred for early as well as later stages of the drug discovery process.
High Content Screening Market Drivers, Restraints, Trends, and Opportunities
-
Rising toxicity studies and increasing demand for novel technologies in cell analysis are expected to propel the market growth.
-
Growing requirement for cost containment in the pharmaceutical industry is driving the market.
-
High cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of HCS instruments are expected to restrain the market growth.
-
The growth in funding for cellular research and technological advancements in HCS solutions is expected to drive the market.
Scope of High Content Screening Market Report
The report on the global high content screening market includes an assessment of the market, trends, segments and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
High Content Screening Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023 – 2031
|
Segmentation
|
Types of Products (Instruments, Consumables, Software, and Others), Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling, and Others), End-users (Pharmaceutical and Biotechnology Companies, Academic and Government Institutions, and Contract Research Organizations)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Becton, Dickinson and Company, Perkinelmer Inc., Danaher Corporation, Thermo Fisher Scientific Inc., GE Healthcare
|
High Content Screening Market Segment Insights
Instruments segment to account a major market share
Based on the types of products, the market is divided as instruments, consumables, software, and others. The instruments segment is expected to account for a major market share during the forecast period. The advancements in instrumentation and automation techniques are anticipated to propel the segment growth. Companies are developing automated solutions such as instruments with advanced visualization capability, in line with the enhanced software platform. Moreover, increasing funds for product development is boosting the segment growth.
Toxicity studies segment to expand at a rapid pace
On the basis of applications, the market is segregated into primary and secondary screening, target identification and validation, toxicity studies, compound profiling, and others. The toxicity studies segment is projected to expand at a rapid pace during the forecast period due to increasing use of HCS in the toxicity studies.
Pharmaceutical and biotechnology companies segment to account a significant market share
In terms of end-users, the market is divided as pharmaceutical and biotechnology companies, academic and government institutions, and contract research organization. The pharmaceutical and biotechnology companies segment is projected to account for a significant market share during the forecast period owing to the increased use of HCS in drug discovery processes.
The market in Asia Pacific to exhibit a robust CAGR
Based on regions, the market is segregated into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in Asia Pacific is expected to exhibit a high CAGR during the forecast period. The market growth is attributed to increasing drug discovery research, growing focus of multinational companies on emerging markets, and developing R&D infrastructure. Moreover, research and development programs are carried out by manufacturers to improve the cell analyzers and flow cytometers in the high content screening market are spurring the regional market growth.
Segments
Types of Products
- Instruments
- Consumables
- Software
- Others
Application
- Primary and Secondary Screening
- Target Identification and Validation
- Toxicity Studies
- Compound Profiling
- Others
End-users
- Pharmaceutical and Biotechnology Companies
- Academic and Government Institutions
- Contract Research Organization
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key players
Competitive Landscape
Some of the major players in this market are Becton, Dickinson and Company, Perkinelmer Inc., Danaher Corporation, Thermo Fisher Scientific Inc., GE Healthcare.
For compound profiling applications, many pharmaceutical companies are partnering with contract research organizations to identify potential candidates for drug discovery.